FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial

​

Quoin Pharmaceuticals has received FDA clearance for its IND application for QRX003, enabling it to initiate a Phase II clinical trial for a treatment for Peeling Skin Syndrome (PSS).

The post FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial appeared first on Hospital Management.

 

Back to the Featured Stories
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial

Featured Stories

Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Smith+Nephew unveils Lynx Coblation Laryngeal Wand for laryngology
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
Neuraptive secures exclusive licence from Washington University for nerve device

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us